|
|
|
Pronunciation |
|
(floo
oh SIN oh
nide) |
|
|
U.S. Brand
Names |
|
Lidex®; Lidex-E® |
|
|
Generic
Available |
|
Yes |
|
|
Canadian Brand
Names |
|
Lyderm; Lydonide; Tiamol®;
Topactin®; Topsyn® |
|
|
Pharmacological Index |
|
Corticosteroid, Topical |
|
|
Use |
|
Anti-inflammatory, antipruritic, relief of inflammatory and pruritic
manifestations [high potency topical corticosteroid] |
|
|
Pregnancy Risk
Factor |
|
C |
|
|
Contraindications |
|
Viral, fungal, or tubercular skin lesions, herpes simplex, known
hypersensitivity to fluocinonide |
|
|
Warnings/Precautions |
|
Adverse systemic effects may occur when used on large areas of the body,
denuded areas, for prolonged periods of time, with an occlusive dressing, and/or
in infants or small children |
|
|
Adverse
Reactions |
|
<1%: Intracranial hypertension, acne, hypopigmentation, allergic
dermatitis, maceration of the skin, skin atrophy, dry skin, itching,
folliculitis, hypertrichosis, HPA suppression, Cushing's syndrome, growth
retardation, burning, irritation, secondary infection |
|
|
Drug
Interactions |
|
No data reported |
|
|
Mechanism of
Action |
|
Fluorinated topical corticosteroid considered to be of high potency. The
mechanism of action for all topical corticosteroids is not well defined,
however, is felt to be a combination of three important properties:
anti-inflammatory activity, immunosuppressive properties, and antiproliferative
actions. |
|
|
Pharmacodynamics/Kinetics |
|
Absorption: Dependent on amount applied and nature of skin at application
site; ranges from ~1% in areas of thick stratum corneum (palms, soles, elbows,
etc) to 36% in areas of thin stratum corneum (face, eyelids, etc); absorption is
increased in areas of skin damage, inflammation, or occlusion
Distribution: Distributed throughout local skin; any absorbed drug is removed
rapidly from the blood and distributed into muscle, liver, skin, intestines, and
kidneys
Metabolism: Primarily in the skin; small amount absorbed into systemic
circulation is metabolized primarily in the liver to inactive compounds
Elimination: By the kidneys primarily as glucuronides and sulfates, but also
as unconjugated products; small amounts of metabolites are excreted in feces
|
|
|
Usual Dosage |
|
Children and Adults: Topical: Apply thin layer to affected area 2-4 times/day
depending on the severity of the condition. Therapy should be discontinued when
control is achieved; if no improvement is seen, reassessment of diagnosis may be
necessary. |
|
|
Dental Health: Local
Anesthetic/Vasoconstrictor
Precautions |
|
No information available to require special precautions |
|
|
Dental Health:
Effects on Dental Treatment |
|
No effects or complications reported |
|
|
Patient
Information |
|
Do not use tight-fitting diapers or plastic pants on children being treated
in the diaper area; use only as prescribed, and for no longer than the period
prescribed; apply sparingly in a light film; rub in lightly; notify physician if
condition being treated persists or worsens; avoid contact with
eyes |
|
|
Nursing
Implications |
|
Use sparingly |
|
|
Dosage Forms |
|
Cream: 0.05% (15 g, 30 g, 60 g, 120 g)
Anhydrous, emollient (Lidex®): 0.05% (15 g, 30 g, 60 g,
120 g)
Aqueous, emollient (Lidex-E®): 0.05% (15 g, 30 g, 60 g,
120 g)
Gel, topical: 0.05% (15 g, 60 g)
Lidex®: 0.05% (15 g, 30 g, 60 g, 120 g)
Ointment, topical: 0.05% (15 g, 30 g, 60 g)
Lidex®: 0.05% (15 g, 30 g, 60 g, 120 g)
Solution, topical: 0.05% (20 mL, 60 mL)
Lidex®: 0.05% (20 mL, 60 mL)
|
|
Copyright © 1978-2000 Lexi-Comp Inc. All Rights Reserved
| |